BRAF and non-small cell lung carcinoma: ctDNA profiling in BRAF-mutated NSCLC has yielded significant insights into the molecular underpinnings of resistance to BRAF-targeted therapy (TT), implicating reactivation of the MAPK and PI3K signaling pathways as well as alterations in downstream signal transducers [91].